Vyne Therapeutics Inc (VYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -26,483 | -39,834 | -28,452 | -23,210 | -73,329 |
| Depreciation Amortization | -755 | -2,439 | -255 | 72 | 109 |
| Accounts receivable | 4,214 | -899 | 405 | 11,210 | N/A |
| Other Working Capital | -8,194 | 4,999 | 60 | 2,277 | 4,776 |
| Other Operating Activity | -1,906 | 4,201 | 2,901 | -19,549 | 12,077 |
| Operating Cash Flow | $-33,124 | $-33,972 | $-25,341 | $-29,200 | $-56,367 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 68,300 | 84,000 | -62,354 | N/A | N/A |
| PPE Investments | N/A | -117 | N/A | N/A | N/A |
| Net Acquisitions | N/A | N/A | 5,000 | 15,667 | N/A |
| Purchase Of Investment | -30,932 | -60,518 | N/A | N/A | N/A |
| Sale Of Investment | N/A | N/A | N/A | N/A | 1,027 |
| Investing Cash Flow | $37,368 | $23,365 | $-57,354 | $15,667 | $1,027 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | N/A | N/A | -36,432 |
| Common Stock Issued | N/A | N/A | 82,821 | 1,470 | 76,503 |
| Other Financing Activity | -143 | -141 | -427 | 183 | -294 |
| Financing Cash Flow | $-143 | $-141 | $82,394 | $1,653 | $39,777 |
| Beginning Cash Position | 19,926 | 30,674 | 30,975 | 42,855 | 58,418 |
| End Cash Position | 24,027 | 19,926 | 30,674 | 30,975 | 42,855 |
| Net Cash Flow | $4,101 | $-10,748 | $-301 | $-11,880 | $-15,563 |
| Free Cash Flow | |||||
| Operating Cash Flow | -33,124 | -33,972 | -25,341 | -29,200 | -56,367 |
| Capital Expenditure | N/A | -117 | N/A | N/A | N/A |
| Free Cash Flow | -33,124 | -34,089 | -25,341 | -29,200 | -56,367 |